176 related articles for article (PubMed ID: 19032125)
21. Retrospective comparison of early versus late treatment with fluticasone propionate/salmeterol after an asthma exacerbation.
Hagiwara M; Delea TE; Stanford RH
J Asthma; 2011 Sep; 48(7):721-8. PubMed ID: 21793768
[TBL] [Abstract][Full Text] [Related]
22. Adherence to asthma controller medication regimens.
Stempel DA; Stoloff SW; Carranza Rosenzweig JR; Stanford RH; Ryskina KL; Legorreta AP
Respir Med; 2005 Oct; 99(10):1263-7. PubMed ID: 16140227
[TBL] [Abstract][Full Text] [Related]
23. Dispensing of fluticasone propionate/salmeterol combination in the summer and asthma-related outcomes in the fall.
Spahn J; Sheth K; Yeh WS; Stempel DA; Stanford RH
J Allergy Clin Immunol; 2009 Dec; 124(6):1197-203. PubMed ID: 19910037
[TBL] [Abstract][Full Text] [Related]
24. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.
Friedman HS; Eid NS; Crespi S; Wilcox TK; Reardon G
Clin Ther; 2009 May; 31(5):1056-63. PubMed ID: 19539106
[TBL] [Abstract][Full Text] [Related]
25. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies.
Stoloff SW; Stempel DA; Meyer J; Stanford RH; Carranza Rosenzweig JR
J Allergy Clin Immunol; 2004 Feb; 113(2):245-51. PubMed ID: 14767437
[TBL] [Abstract][Full Text] [Related]
26. Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a Medicare-eligible population.
Stanford RH; Blanchette CM; Roberts MH; Petersen H; Fuhlbrigge AL
Am J Geriatr Pharmacother; 2012 Dec; 10(6):343-51. PubMed ID: 23083688
[TBL] [Abstract][Full Text] [Related]
27. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
Markham A; Jarvis B
Drugs; 2000 Nov; 60(5):1207-33. PubMed ID: 11129128
[TBL] [Abstract][Full Text] [Related]
28. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy.
Dalal AA; Shah M; D'Souza AO; Crater GD
Respir Med; 2012 Jun; 106(6):829-37. PubMed ID: 22425138
[TBL] [Abstract][Full Text] [Related]
29. Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids.
Chan J; Hui RL; Spence MM
J Manag Care Pharm; 2007; 13(1):21-7. PubMed ID: 17269833
[TBL] [Abstract][Full Text] [Related]
30. Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens.
O'Connor RD; Rosenzweig JR; Stanford RH; Gilmore AS; Ryskina KL; Legorreta AP; Stempel DA
Ann Allergy Asthma Immunol; 2005 Dec; 95(6):535-40. PubMed ID: 16400892
[TBL] [Abstract][Full Text] [Related]
31. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
32. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
33. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database.
Miller DP; Watkins SE; Sampson T; Davis KJ
Int J Chron Obstruct Pulmon Dis; 2011; 6():467-76. PubMed ID: 22003292
[TBL] [Abstract][Full Text] [Related]
34. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.
Kern DM; Davis J; Williams SA; Tunceli O; Wu B; Hollis S; Strange C; Trudo F
Respir Res; 2015 Apr; 16(1):52. PubMed ID: 25899176
[TBL] [Abstract][Full Text] [Related]
35. Maintenance asthma treatment with fluticasone/salmeterol combination via Diskus: effect on outcomes in inner-city children enrolled in TennCare.
Nguyen WT; Stewart C; Fisher K; Tolley E; Lew DB; Self TH
Allergy Asthma Proc; 2005; 26(2):129-34. PubMed ID: 15971472
[TBL] [Abstract][Full Text] [Related]
36. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma.
Miller E; Sears MR; McIvor A; Liovas A
Can Respir J; 2007; 14(5):269-75. PubMed ID: 17703241
[TBL] [Abstract][Full Text] [Related]
37. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
Dalal AA; Candrilli SD; Davis KL
Manag Care; 2011 Aug; 20(8):46-50, 53-5. PubMed ID: 21887993
[TBL] [Abstract][Full Text] [Related]
38. Inhaled salmeterol/fluticasone propionate: a review of its use in asthma.
Reynolds NA; Lyseng-Williamson KA; Wiseman LR
Drugs; 2005; 65(12):1715-34. PubMed ID: 16060707
[TBL] [Abstract][Full Text] [Related]
39. Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching.
Roberts MH; Dalal AA
Int J Chron Obstruct Pulmon Dis; 2012; 7():221-33. PubMed ID: 22500122
[TBL] [Abstract][Full Text] [Related]
40. Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma.
O'Connor RD; O'Donnell JC; Pinto LA; Wiener DJ; Legorreta AP
Chest; 2002 Apr; 121(4):1028-35. PubMed ID: 11948029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
